1. Medtech Insight
  2. >>Business
  3. >>Strategy

Diagnostics For All Set To Take The Field For Clinical Trials

Not-for-profit start-up Diagnostics for All is set to begin a field trial in Kenya in March to evaluate a postage stamp-sized disposable diagnostic device to assess liver function in AIDS and TB patients. But the company eschews the notion that it's a charitable endeavor. Rather, it has crafted a licensing deal and business model that anticipates leveraging its not-for-profit work into a sustainable commercial First World business.

With more than $10 million in funding from the Gates Foundation and other grant sources and a network of volunteer professionals to bolster its six-person staff, not-for-profit start-up Diagnostics for All (DFA) is set to begin a field trial in Kenya in March to evaluate its energy- and water-independent, postage stamp-sized diagnostic device to assess liver function in AIDS and tuberculosis patients. But the company, launched out of the Harvard University laboratory of George Whitesides, PhD, eschews the notion that it's a charitable endeavor. Rather, CEO Una Ryan, PhD, and Harvard have crafted a licensing deal and business model that anticipates leveraging its not-for-profit work in the developing world into a sustainable commercial First World business.

DFA is built around a Whitesides' technology for running clinical chemistries and immunoassays using a single-use disposable. The device is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 
• By Natasha Barrow

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

More from Business

Inaccurate Carbon Dioxide Readings Prompt Class I Recall Of Draeger Ventilation Filters

 
• By Brian Bossetta

Draeger Medical has recalled certain SafeStar and TwinStar ventilation filters after reports of serious injuries caused by misleading carbon dioxide readings.

After Thought-Control Demo, Synchron Plans Pilot Study With Upgraded BCI On Path To Pivotal Trial

 
• By Marion Webb

Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 
• By Natasha Barrow

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.